Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 4/20 | 0.31 |
| ▸ | FDPS | P14324 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 4/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31233959 | 1.00 | MAPT (0.37) | MAPTLMNADNM1OPRM1CES1 | |
| SCHEMBL16682860 | 1.00 | MAPT (0.37) | MAPTLMNADNM1OPRM1CES1 | |
| SCHEMBL2048920 | 0.98 | MAPT (0.38) | MAPTLMNADNM1OPRM1CES1 | |
| SCHEMBL31316959 | 0.92 | MAPT (0.39) | MAPTLMNADNM1OPRM1CES1 | |
| SCHEMBL29962840 | 0.92 | DNM1 (0.30) | DNM1 | |
| SCHEMBL29176886 | 0.90 | DNM1 (0.31) | DNM1 | |
| SCHEMBL10643230 | 0.85 | MAPT (0.39) | MAPTLMNACES1FDPSFAAH | |
| SCHEMBL9444812 | 0.85 | MAPT (0.39) | MAPTLMNACES1FDPSFAAH | |
| SCHEMBL16682320 | 0.85 | LMNA (0.33) | LMNA | |
| SCHEMBL461233 | 0.84 | DNM1 (0.32) | DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009085642-A1 | TRIMETHYLSILYL-CAPPED POLYSILOXANE MACROMONOMERS CONTAINING POLAR FLUORINATED SIDE-CHAINS | BAUSCH & LOMB INCORPORATED (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090168013-A1 | Trimethylsilyl-Capped Polysiloxane Macromonomers Containing Polar Fluorinated Side-Chains | BAUSCH & LOMB INCORPORATED | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090168013-A1 | Trimethylsilyl-Capped Polysiloxane Macromonomers Containing Polar Fluorinated Side-Chains | VCL, PCNA, MLEC | MAPT 2071/4885LMNA 631/4885DNM1 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.